Kato ET, et al. – Given that researchers who conducted the DECLARE-TIMI 58 trial demonstrated reduced composite endpoint of cardiovascular (CV) death/hospitalization for heart failure (HHF) using the sodium glucose co-transporter 2 inhibitor (SGLT2i) dapagliflozin in a broad population of patients with type 2 diabetes mellitus, investigators of the current study examined how baseline left ventricular ejection fraction (EF) influences the clinical benefit of SGLT2i. Of 17,160 patients, they noted HF with reduced EF (HFrEF) in 3.9%, HF without known reduced EF in 7.7%, and no history of HF at baseline in 88.4%. Outcomes revealed reduced HHF in patients with and without HFrEF, and reduced CV death and all-cause mortality in patients with HFrEF in correlation to dapagliflozin administration.